Chengdu Kanghua Biological Products (300841.SZ) announced that recently, the company developed a recombinant hexavalent norovirus vaccine (Pichia pastoris...
According to a report from Zhitong Finance APP, Chengdu Kanghua Biological Products (300841.SZ) announced that recently, the company developed a recombinant hexavalent norovirus vaccine (Pichia pastoris) received the "Clinical Trial Approval Notification" issued by the National Medical Products Administration, agreeing to conduct clinical trials for this product.
Upon review, the recombinant hexavalent norovirus vaccine (Pichia pastoris) accepted on September 25, 2024, meets the relevant requirements for pharmaceutical registration, and clinical trials to prevent acute gastroenteritis caused by genotype infections contained in the vaccine are approved.